Predicting benefit from adjuvant therapy in colon cancer
- First Online:
- 35 Downloads
Colorectal cancer is a significant cause of morbidity and mortality despite recent advances in therapy. Given the variety of options that exist for treatment of metastatic colorectal cancer and the fact that resistance to any single approach is common, the need to identify predictors of response to specific therapies is urgent. This need is particularly critical in the adjuvant setting where the stakes are highest in terms of both cure and treatment-associated toxicities. In this manuscript, we review some of the putative markers of prognosis and the effects of treatment that ultimately may play a role in the selection of patients and treatments for the adjuvant therapy of colorectal cancer, with a focus on recent developments and ongoing clinical trials.
Unable to display preview. Download preview PDF.